Key Takeaways
- • Charterhouse Capital Partners' recommended £235.2 million takeover bid for Animalcare Group (ANCR) was agreed by the board in mid-April 2026, marking the likely end of the company's public listing.
- • Animalcare delivered 20% revenue growth to £89.1 million (from £74.2 million) in the year ended December 31, 2025, driven by 1.7% organic growth and a significant contribution from the Randlab acquisition completed in late 2024.
- • Underlying profit margins expanded by approximately 20%, with the Randlab equine veterinary acquisition performing strongly—equine revenue surged 185% to £21.1 million and now represents 24% of group revenues.
- • Charterhouse plans to pursue further M&A activity post-acquisition to continue building Animalcare's position in the high-growth equine veterinary market.
- • Animalcare's share price surged 35% to 333 pence following the takeover announcement, reflecting investor approval of the offer valuation.
Summary
Animalcare Group has attracted private equity attention at a moment of strong operational momentum. On May 7, 2026, the York-based veterinary pharmaceutical company published results that would likely be its final set of accounts as a publicly traded entity, following the board's acceptance of Charterhouse Capital Partners' £235.2 million takeover bid agreed in mid-April.
The financial performance underpinning the transaction is robust. Revenue grew 20% year-over-year to £89.1 million from £74.2 million, underpinned by 1.7% like-for-like organic expansion combined with the material contribution from Randlab, an equine veterinary group acquired for A$120 million (£64 million) in late 2024. Critically for the quality of earnings, underlying profit margins expanded by approximately one-fifth during the period, signaling improved operational leverage and integration efficiency. The integration of Randlab has progressed according to plan, with the equine unit generating £21.1 million in revenue—a 185% increase that reflects both organic momentum and full-period consolidation impact. Equine now accounts for 24% of total group revenues, indicating successful market penetration in a high-growth segment.
The market's reception of both results and takeover terms has been unambiguously positive. Animalcare's share price rallied 35% to 333 pence in the hours following the Charterhouse announcement, suggesting shareholders view the £235.2 million valuation as fair compensation relative to near-term earnings trajectory and growth prospects. The takeover attracted institutional advisory firepower: Norton Rose Fulbright advised on the transaction, with Rothschild positioned as financial adviser to Charterhouse.
Charterhouse has signaled clear intentions to pursue additional M&A activity post-acquisition, positioning Animalcare for continued consolidation within the veterinary pharmaceuticals sector. The private equity group's interest in the asset reflects confidence in both current management execution and market tailwinds within equine and broader animal health, particularly given the demonstrated margin expansion and successful integration playbook demonstrated through Randlab.
The financial performance underpinning the transaction is robust. Revenue grew 20% year-over-year to £89.1 million from £74.2 million, underpinned by 1.7% like-for-like organic expansion combined with the material contribution from Randlab, an equine veterinary group acquired for A$120 million (£64 million) in late 2024. Critically for the quality of earnings, underlying profit margins expanded by approximately one-fifth during the period, signaling improved operational leverage and integration efficiency. The integration of Randlab has progressed according to plan, with the equine unit generating £21.1 million in revenue—a 185% increase that reflects both organic momentum and full-period consolidation impact. Equine now accounts for 24% of total group revenues, indicating successful market penetration in a high-growth segment.
The market's reception of both results and takeover terms has been unambiguously positive. Animalcare's share price rallied 35% to 333 pence in the hours following the Charterhouse announcement, suggesting shareholders view the £235.2 million valuation as fair compensation relative to near-term earnings trajectory and growth prospects. The takeover attracted institutional advisory firepower: Norton Rose Fulbright advised on the transaction, with Rothschild positioned as financial adviser to Charterhouse.
Charterhouse has signaled clear intentions to pursue additional M&A activity post-acquisition, positioning Animalcare for continued consolidation within the veterinary pharmaceuticals sector. The private equity group's interest in the asset reflects confidence in both current management execution and market tailwinds within equine and broader animal health, particularly given the demonstrated margin expansion and successful integration playbook demonstrated through Randlab.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.